Oxford Biomedica (uk) Limited

Oxford Biomedica, Inc.

Narry Kim

Alan John Kingsman

Kyriacos Andreou Mitrophanous

Susan Mary Kingsman

Miles William Carroll

Jonathan Rohll

A viral vector production system is provided which system comprises: The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.

Antiviral vectors

Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

Retroviral vectors

Anti-viral vectors

A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.

Equine infectious anemia virus vectors

Growing community of inventors

Seoul, South Korea

Narry Kim